Unknown OBSERVATIONAL NCT05043272

Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI

Sponsor: The Second Affiliated Hospital of Chongqing Medical University

Updated 4 times since 2021 Last updated: Sep 10, 2021 Started: Aug 1, 2021 Primary completion: May 1, 2022 Completion: Aug 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05043272, this observational or N/A phase trial focuses on Covid19 and Overweight and remains ongoing. Sponsored by The Second Affiliated Hospital of Chongqing Medical University, it has been updated 4 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Oct 2021 — Oct 2023 [monthly]

Recruiting

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Second Affiliated Hospital of Chongqing Medical University

Data source: The Second Affiliated Hospital of Chongqing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China